LSE · IGET.L
Invesco Global Equity Income Trust
£4.03-£0.02 (-0.49%)
Invesco Global Equity Income Trust’s quoted price sits in the upper half of its reported 52-week range, 12.39% below the high.
Loading market information…
LSE · IBT.L · GBp
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 01:53 PM UTC. Cached market data; not a live quote.
One-year closing-price history · GBp. Historical prices are not a forecast.
International Biotechnology Trust plc’s quoted price sits in the upper half of its reported 52-week range, 14.57% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
International Biotechnology Trust plc’s forward annual dividend is £0.31 per share, paid semi-annual. The forward yield is 2.97% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
International Biotechnology Trust plc’s next earnings report is currently expected on Nov 3, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow International Biotechnology Trust plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
International Biotechnology Trust plc focuses its capital allocation primarily on companies in their development and late-stage phases. A substantial portion of its assets is dedicated to publicly traded small and mid-capitalization enterprises, with a smaller allocation to larger listed firms. Pursuing a long-only investment approach, the Trust targets both quoted and unquoted biotechnology and life sciences companies, particularly those involved in drug discovery and development. Related sectors of interest encompass microbiology, broader life sciences, pharmaceutical research and development, gene research and development, medical devices, and healthcare services. The fund actively seeks out companies engaged in the creation, advancement, and commercialization of novel products, medical devices, or foundational technologies, including those within the therapeutic sub-sector. A key criterion for investment is a strong growth outlook, often driven by the successful development or market introduction of a biotechnology drug candidate, medical device, or other innovative medical research tool. Investments may also extend to specialty pharmaceuticals and life science instrumentation. The spectrum of investee companies ranges from early-stage private firms with robust scientific foundations requiring development capital, to established, multi-billion dollar biotechnology and medical device corporations with extensive product portfolios already widely adopted in global healthcare settings. While the majority of its capital is deployed in smaller and mid-cap publicly traded entities, the Trust aims to commit up to 30% of its assets to privately held ventures. It allows for an aggregate exposure to unquoted companies of up to 40% at the time of initial investment, accounting for any valuation increases and subsequent funding. Although the United States represents a typical geographical focus, the Trust actively seeks optimal investment opportunities worldwide, including in Western Europe, Australia, and Asia. Individual investments in portfolio companies generally range from $1 million to $4 million. Exits for its unquoted holdings are typically realized either through their sale to strategic acquirers, such as major pharmaceutical corporations, or, in certain instances, via public flotation (IPO).
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:01 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
Latest available per-share figures in GBP. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£4.03-£0.02 (-0.49%)
Invesco Global Equity Income Trust’s quoted price sits in the upper half of its reported 52-week range, 12.39% below the high.
£0.74+£0.02 (+2.07%)
British Smaller Companies VCT plc’s quoted price sits in the upper half of its reported 52-week range, 4.52% below the high.
£2.56+£0.01 (+0.45%)
Aurora UK Alpha plc’s quoted price sits in the lower half of its reported 52-week range, 14.48% below the high.
£1.05£0.00 (0.0%)
Albion Enterprise VCT PLC’s quoted price sits in the upper half of its reported 52-week range, 5.0% below the high.
£13.80-£0.14 (-1.0%)
The Biotech Growth Trust PLC’s quoted price sits in the lower half of its reported 52-week range, 22.73% below the high.
£0.64£0.00 (0.0%)
Albion Technology & General VCT PLC’s quoted price sits in the upper half of its reported 52-week range, 7.3% below the high.
£2.27-£0.01 (-0.39%)
STS Global Income & Growth Trust PLC’s quoted price sits in the lower half of its reported 52-week range, 8.05% below the high.
£5.37-£0.05 (-0.92%)
abrdn UK Smaller Companies Growth Trust plc’s quoted price sits in the upper half of its reported 52-week range, 4.9% below the high.
